Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating giant cell arteritis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6299

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 January 2025 - 20 February 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6299
23 January 2025 In progress. Scoping commencing
06 December 2024 Please note that following on from a request received from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin in mid-March 2025 when we will write to you about how you can get involved.
13 May 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.  In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. 
28 April 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual